0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Observation |

Cerebral Infarcts in the Setting of Eosinophilia Three Cases and a Discussion FREE

Hartej S. Sethi, MBBS; James W. Schmidley, MD
[+] Author Affiliations

Author Affiliations: Department of Neurology, University of Arkansas for Medical Sciences, Little Rock.


Arch Neurol. 2010;67(10):1275-1277. doi:10.1001/archneurol.2010.256.
Text Size: A A A
Published online

ABSTRACT

Objective  To describe 3 cases of stroke associated with hypereosinophilic syndrome and discuss the pathogenesis of such strokes.

Design  Retrospective medical record review.

Setting  University hospital.

Participants  Three patients who had strokes temporally correlating with eosinophilia with no other obvious causes of stroke.

Intervention  Retrospective review of the hospital course, laboratory data, imaging, treatment, and outcome.

Results  All 3 patients had multiple strokes in both hemispheres. Two patients with modest eosinophilia that was controlled quickly had infarcts mostly in arterial border zones and had good outcomes. The third patient with severe and more refractory eosinophilia had a poor outcome.

Conclusions  Cardiac emboli and direct eosinophil toxicity contribute to strokes in hypereosinophilic syndrome. Prognosis is variable with use of anticoagulation and antiplatelet agents but rapid lowering of the eosinophil count results in a better outcome.

Figures in this Article

REPORT OF CASES

CASE 1

A 52-year-old, right-handed man presented 4 days after sudden onset of right-sided weakness and slurring of speech. His medical history included hypertension, emphysema, smoking, and alcohol abuse. On neurological examination, he had dysarthria, right facial droop, and right-sided weakness affecting the leg more than the arm. His white blood cell (WBC) count was 16 900/μL (to convert to ×109/L, multiply by 0.001) with 44.6% eosinophils. Results of cerebrospinal fluid testing were normal. Magnetic resonance imaging (MRI) of the brain showed multiple areas of restricted diffusion, representing infarctions, in anterior and posterior border zones (Figure 1). Findings of magnetic resonance angiography of the head and neck and transesophageal echocardiography were unremarkable. An extensive search for the cause of eosinophilia including stool testing for ova and parasites, cryptococcal antigen, thyroid studies, human immunodeficiency virus, and bone marrow biopsy were unremarkable. The patient was treated with aspirin. The eosinophil count declined over the following few weeks without intervention. Two months after discharge, he had minimal residual right-sided weakness and his WBC count was 9500/μL with 26% eosinophils. The patient did not keep further return appointments.

Place holder to copy figure label and caption
Figure 1.

Diffusion-weighted magnetic resonance image of patients 1 (A) and 2 (B) showing border zone infarcts.

Graphic Jump Location
CASE 2

A 47-year-old previously healthy man presented with right flank and leg pain. On examination, he was febrile with trace pedal edema, positive Homan sign, and benign findings on abdominal examination. Findings of neurological examination were unremarkable. His WBC count was 27 000/μL with 70% eosinophils. Electrocardiogram and cardiac enzyme testing revealed anterior wall myocardial infarction but findings of coronary angiography were normal. Venous dopplers of the legs revealed bilateral deep venous thrombosis. With initiation of anticoagulation, the pain resolved and the patient was discharged. A week later he was back with shortness of breath and bilateral leg weakness. Neurological examination showed apathy with generalized weakness but no lateralizing signs and no cranial nerve abnormalities. His WBC count had dropped to 18 900/μL with 57% eosinophils (international normalized ratio, 1.9). Computed tomography angiography of the chest revealed multiple small pulmonary emboli. Results of a hypercoagulable panel, rheumatological panel, Coxsackie viral antigen test, parvovirus B19 antigen test, Rocky Mountain spotted fever (RMSF) antigen test, and stool test for ova and parasites were all unremarkable. An MRI of the brain showed multiple small acute infarcts in all arterial border zones (Figure 1). Transthoracic echocardiogram (TTE) revealed mildly reduced ejection fraction but no evidence of fibrosis or thrombosis. Bone marrow biopsy showed 70% cellularity with increased eosinophil precursors but no abnormal cell populations. The patient was diagnosed with hypereosinophilic syndrome (HES), and treatment with oral steroids was started. The eosinophilia responded well, and the absolute eosinophil count normalized within 3 days. The patient was discharged to inpatient rehabilitation and continued taking low-dose steroids. At the 1-year follow-up, findings of neurological examination and eosinophil count were normal.

CASE 3

A 46-year-old woman presented to a community hospital with chest pain. She reported having had flulike symptoms and a diffuse red rash 2 weeks prior. Findings of electrocardiogram and cardiac enzyme testing were consistent with inferior wall myocardial infarction. Coronary angioplasty with stent placement did not relieve her chest pain. Two days later, she became somnolent and developed spasticity in all extremities. At this point, she was transferred to our institution. On examination, she did not respond to verbal stimuli but painful stimulation induced moaning and decorticate posturing. All extremities were severely spastic, with exaggerated reflexes and bilateral ankle clonus. Her WBC count was 73 000/μL with 93% eosinophils. No cause for eosinophilia was discovered. Transthoracic echocardiogram showed an ejection fraction of 45% with no mural thrombi or valve abnormalities. Bone marrow aspiration did not show any abnormal cell populations. Magnetic resonance imaging of the brain revealed multiple acute strokes (Figure 2). She did not respond to steroid treatment. Imatinib therapy was initiated, and her eosinophil count slowly trended down. Three weeks into her hospital course, she developed generalized flaccidity. Nerve conduction studies showed severe axonal neuropathy. No eosinophilic infiltrate or inflammation was seen in the nerve biopsy. Muscle biopsy showed fiber size variation and minor denervation changes. Seven months after initial presentation, her eosinophil count was normal. She was still in a nursing home, with minimal improvement. She could only say “yes” and “no” reliably, was unable to lift any limb against gravity, and was hypotonic and areflexic.

Place holder to copy figure label and caption
Figure 2.

Diffusion-weighted magnetic resonance image showing multiple embolic strokes in patient 3.

Graphic Jump Location

COMMENT

The presence of an absolute eosinophil count greater than 1500/μL for 6 months without any known triggers or evidence of related end-organ damage are the criteria for HES.1

A large series of patients with HES in 19722 noted high prevalence of neurological sequelae, mainly peripheral neuropathy, stroke, and encephalopathy.

Stroke is the most devastating neurological consequence of eosinophilia. Stroke incidence in HES has been estimated to be around 12%.3,4 Case series of eosinophilia-related strokes have projected a common theme: multiple strokes in different vascular territories.4 In early HES, strokes are small and occur in the arterial border zones. If eosinophilia persists, larger cortical and subcortical areas are involved. Cardiac embolism is the likely cause. Eosinophilia can damage the endocardium and myocardium, rendering the heart a potential source of emboli.5 Toxicity by release of eosinophilic basic proteins initiates endomyocardial necrosis. Autopsies of these patients have shown eosinophils and their products in the endomyocardium and in the endothelium of coronary vessels.6 This damage occurs early in the course and is usually subclinical. It progresses in 4 to 6 weeks to a second, thrombotic, stage that results from excessive release of tissue factor by the damaged tissue and from eosinophils,5,7 causing distant embolism. This is followed by the final stage of endomyocardial fibrosis. At this stage, TTE reveals a restrictive cardiomyopathic pattern. Cardiac MRI may be the more sensitive noninvasive modality for detecting ventricular thrombi and myocardial inflammation.8 Endocardial biopsy remains the criterion standard for diagnosis of endomyocardial fibrosis.

In the first 2 stages of HES, when a patient presents with stroke, TTE findings are typically nonrevealing, as in our cases. Half of patients with eosinophilia have cardiac abnormalities by echocardiography.9 Lack of evidence of cardiac disease in some patients with HES suggests that alternate causes must contribute to some of the early strokes. Eosinophils have the potential to cause local thrombogenicity. They store tissue factor in their specific granules,10 and they can induce tissue factor secretion by the endothelium.11 This could be an important cause of small strokes that are limited to the border zones early in HES. Such small infarcts were seen in our first 2 patients and are generally associated with a good prognosis. Patients with multiple emboli tend to have a poor prognosis, as seen in our third patient.

A syndrome of generalized encephalopathy has been described in a small percentage of patients with HES.3 The hallmark of this is behavioral disturbances and upper motor neuron signs. Most of these studies were from the pre-MRI era. An imaging series published in 2001 described 3 patients with eosinophilia-related encephalopathy in whom sequential MRIs of the brain revealed multiple lesions in border zones that worsened with increasing eosinophilia and improved with treatment.12 Pathology on one of these cases was consistent with cerebral infarctions. It seems likely that multiple small infarcts cause eosinophilic encephalopathy, although they are not always recognized clinically.

Not surprisingly, treatment with anticoagulants has been used but the response to anticoagulation alone has been dismal.2 This underscores the importance of rapidly lowering the eosinophil count. For effective treatment strategies to lower eosinophil count, better understanding of the pathophysiology of HES is needed. It can be divided on the basis of etiology into lymphocytic and myeloproliferative variants. The former, which is more common, results from increased secretion of eosinophilic cytokines like interleukin 5 by T lymphocytes.11 Nearly 30% of patients with idiopathic HES have the lymphocytic variant. The eosinophilia in these patients is typically less severe than in those with myeloproliferative HES but is harder to treat.11 The myeloproliferative variant is found in 3% to 27% of HES cases in different series.11 It results from clonal expansion of eosinophilic precursors due to various mutations. The best studied of these is the FIP1L1 gene translocation to platelet-derived growth factor receptor α (PDGFRα) gene, resulting in a fusion product. This product constitutively activates a tyrosine kinase domain on PDGFRα, activating the downstream second messenger systems and enhancing proliferation and survival of eosinophil precursors. PDGFRα tyrosine kinase is competitively inhibited by imatinib mesylate. It binds to the adenosine triphosphate–binding site on PDGFRα tyrosine kinase and prevents tyrosine phosphorylation.13 Its potential cardiotoxicity notwithstanding,14 imatinib has been extremely successful in the treatment of HES related to FIP1L1 mutation. In the absence of this specific cause, steroids and nonspecific immune suppression remain the mainstays of treatment.

ARTICLE INFORMATION

Correspondence: Hartej S. Sethi, MBBS, Department of Neurology, University of Arkansas for Medical Sciences, 4301 W Markham St, Slot 500, Little Rock, AR 72205 (drhartejsingh@gmail.com).

Accepted for Publication: January 17, 2010.

Author Contributions:Study concept and design: Sethi. Acquisition of data: Sethi and Schmidley. Analysis and interpretation of data: Schmidley. Drafting of the manuscript: Sethi. Critical revision of the manuscript for important intellectual content: Schmidley. Administrative, technical, and material support: Sethi and Schmidley. Study supervision: Schmidley.

Financial Disclosure: None reported.

REFERENCES

Chusid  MJDale  DCWest  BCWolff  SM The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975;54 (1) 1- 27
PubMed Link to Article
Moore  PMHarley  JBFauci  AS Neurologic dysfunction in the idiopathic hypereosinophilic syndrome. Ann Intern Med 1985;102 (1) 109- 114
PubMed Link to Article
Fauci  ASHarley  JBRoberts  WCFerrans  VJGralnick  HRBjornson  BH NIH conference: the idiopathic hypereosinophilic syndrome: clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 1982;97 (1) 78- 92
PubMed Link to Article
Chang  WLLin  HJCheng  HH Hypereosinophilic syndrome with recurrent strokes: a case report. Acta Neurol Taiwan 2008;17 (3) 184- 188
PubMed
Ogbogu  PURosing  DRHorne  MK  III Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007;27 (3) 457- 475
PubMed Link to Article
Sekiguchi  MYu  ZXTake  M  et al.  Ultrastructural features of the endomyocardium in patients with eosinophilic heart disease: an endomyocardial biopsy study. Jpn Circ J 1984;48 (12) 1375- 1382
PubMed Link to Article
Moosbauer  CMorgenstern  ECuvelier  SL  et al.  Eosinophils are a major intravascular location for tissue factor storage and exposure. Blood 2007;109 (3) 995- 1002
PubMed Link to Article
Syed  ISMartinez  MWFeng  DLGlockner  JF Cardiac magnetic resonance imaging of eosinophilic endomyocardial disease. Int J Cardiol 2008;126 (3) e50- e52
PubMed Link to Article
Ommen  SRSeward  JBTajik  AJ Clinical and echocardiographic features of hypereosinophilic syndromes. Am J Cardiol 2000;86 (1) 110- 113
PubMed Link to Article
Wang  JGMahmud  SAThompson  JAGeng  JGKey  NSSlungaard  A The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states. Blood 2006;107 (2) 558- 565
PubMed Link to Article
Tefferi  APatnaik  MMPardanani  A Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 2006;133 (5) 468- 492
PubMed Link to Article
Kwon  SUKim  JCKim  JS Sequential magnetic resonance imaging findings in hypereosinophilia-induced encephalopathy. J Neurol 2001;248 (4) 279- 284
PubMed Link to Article
Pardanani  AKetterling  RPLi  CY  et al.  FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 2006;30 (8) 965- 970
PubMed Link to Article
Kerkelä  RGrazette  LYacobi  R  et al.  Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12 (8) 908- 916
PubMed Link to Article

Figures

Place holder to copy figure label and caption
Figure 1.

Diffusion-weighted magnetic resonance image of patients 1 (A) and 2 (B) showing border zone infarcts.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Diffusion-weighted magnetic resonance image showing multiple embolic strokes in patient 3.

Graphic Jump Location

Tables

References

Chusid  MJDale  DCWest  BCWolff  SM The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975;54 (1) 1- 27
PubMed Link to Article
Moore  PMHarley  JBFauci  AS Neurologic dysfunction in the idiopathic hypereosinophilic syndrome. Ann Intern Med 1985;102 (1) 109- 114
PubMed Link to Article
Fauci  ASHarley  JBRoberts  WCFerrans  VJGralnick  HRBjornson  BH NIH conference: the idiopathic hypereosinophilic syndrome: clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 1982;97 (1) 78- 92
PubMed Link to Article
Chang  WLLin  HJCheng  HH Hypereosinophilic syndrome with recurrent strokes: a case report. Acta Neurol Taiwan 2008;17 (3) 184- 188
PubMed
Ogbogu  PURosing  DRHorne  MK  III Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007;27 (3) 457- 475
PubMed Link to Article
Sekiguchi  MYu  ZXTake  M  et al.  Ultrastructural features of the endomyocardium in patients with eosinophilic heart disease: an endomyocardial biopsy study. Jpn Circ J 1984;48 (12) 1375- 1382
PubMed Link to Article
Moosbauer  CMorgenstern  ECuvelier  SL  et al.  Eosinophils are a major intravascular location for tissue factor storage and exposure. Blood 2007;109 (3) 995- 1002
PubMed Link to Article
Syed  ISMartinez  MWFeng  DLGlockner  JF Cardiac magnetic resonance imaging of eosinophilic endomyocardial disease. Int J Cardiol 2008;126 (3) e50- e52
PubMed Link to Article
Ommen  SRSeward  JBTajik  AJ Clinical and echocardiographic features of hypereosinophilic syndromes. Am J Cardiol 2000;86 (1) 110- 113
PubMed Link to Article
Wang  JGMahmud  SAThompson  JAGeng  JGKey  NSSlungaard  A The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states. Blood 2006;107 (2) 558- 565
PubMed Link to Article
Tefferi  APatnaik  MMPardanani  A Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 2006;133 (5) 468- 492
PubMed Link to Article
Kwon  SUKim  JCKim  JS Sequential magnetic resonance imaging findings in hypereosinophilia-induced encephalopathy. J Neurol 2001;248 (4) 279- 284
PubMed Link to Article
Pardanani  AKetterling  RPLi  CY  et al.  FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 2006;30 (8) 965- 970
PubMed Link to Article
Kerkelä  RGrazette  LYacobi  R  et al.  Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12 (8) 908- 916
PubMed Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

2,476 Views
13 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs